Art. 3 Regulation (EC) No 141/2000 of the European Parliament and of the Council of 16 December…

Criteria for designation

In forcesince 7 Aug 2009cited 20×
1.

A medicinal product shall be designated as an orphan medicinal product if its sponsor can establish:

(a)

that it is intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition affecting not more than five in 10 thousand persons in the Community when the application is made, or

that it is intended for the diagnosis, prevention or treatment of a life-threatening, seriously debilitating or serious and chronic condition in the Community and that without incentives it is unlikely that the marketing of the medicinal product in the Community would generate sufficient return to justify the necessary investment;

and

(b)

that there exists no satisfactory method of diagnosis, prevention or treatment of the condition in question that has been authorised in the Community or, if such method exists, that the medicinal product will be of significant benefit to those affected by that condition.

2.

The Commission shall, in accordance with the regulatory procedure referred to in Article 10a(2), adopt the necessary provisions for implementing paragraph 1 of this Article in the form of an implementing Regulation.

The 10 that are cited most themselves, of 20.

  • Commission Regulation (EC) No 847/2000 of 27 April 2000 laying down the provisions for i…123Law

    … факторите, които трябва да се отчитат за прилагането на член 3 от Регламент (ЕО) № 141/2000 за лекарствените продукти-сираци и дава …

  • Judgment of the General Court (Fifth Chamber) of 9 September 2010. Now Pharm AG v European Commission.Decision

    In the first place, it is appropriate to consider the applicant’s argument based on the properties of Ukrain. The applicant contends that, unlike medicinal products already authorised intended for the treatment of pancreatic cancer, …

    9 Sep 2010 · 62008TJ0074

  • Judgment of the General Court (Sixth Chamber), 22 January 2015. Teva Pharma BV and Teva Pharmaceuticals Europe BV v European Medicines AgencDecision

    The applicants put forward two pleas in law in support of their action. The first plea alleges infringement of Article 8(1) and (3) of Regulation No 141/2000 in so far as the EMA misinterpreted those provisions by refusing to validate the …

    22 Jan 2015 · 62012TJ0140

  • Regulation (EC) No 596/2009 of the European Parliament and of the Council of 18 June 200…Lawamends

  • Judgment of the General Court (Second Chamber) of 5 December 2018. Bristol-Myers Squibb Pharma EEIG v European Commission and European MedicDecision

    Furthermore, the Court has stated that it is apparent from the wording of Article 3(1)(b) of Regulation No 141/2000 and the spirit underlying the system established by that regulation that the criteria for a finding of significant benefit …

    5 Dec 2018 · 62016TJ0329

  • Judgment of the General Court (Seventh Chamber) of 16 May 2019 (Extracts). GMP-Orphan (GMPO) v European Commission.Decision

    16 May 2019 · 62017TJ0733

  • Judgment of the General Court (Ninth Chamber) of 26 January 2022. Mylan IRE Healthcare Ltd v European Commission.Decision

    In substance, the applicant claims that the Commission misinterpreted the concept of ‘significant benefit’, referred to in Article 3(2) of Regulation No 141/2000, and the concept of ‘clinical superiority’, referred to in Article …

    26 Jan 2022 · 62016TJ0303

  • Judgment of the General Court (Fifth Chamber) of 9 September 2010. CSL Behring GmbH v European Commission and European Medicines Agency (EMADecision

    In addition, it should be noted that the applicant has not claimed nor, a fortiori, shown that the medicinal product which is the object of the application for designation as an orphan medicinal product would be of significant benefit, …

    9 Sep 2010 · 62007TJ0264

  • Judgment of the Court (Sixth Chamber) of 3 March 2016. Teva Pharma BV and Teva Pharmaceuticals Europe BV v European Medicines Agency (EMA).Decision

    As observed in paragraph 31 above, where a similar medicinal product that has been granted marketing authorisation under Article 8(3) of Regulation No 141/2000 is an orphan medicinal product, it enjoys the market exclusivity provided in …

    3 Mar 2016 · 62015CJ0138

  • Commission Regulation (EC) No 507/2006 of 29 March 2006 on the conditional marketing aut…2Law

    … 2119/98/ES; 3. léčivé přípravky stanovené jako léčivé přípravky pro vzácná onemocnění v souladu s článkem 3 nařízení (ES) č. 141/2000.